2015-04-08 21:48:43 UTC

GI Bleeding and Motility

GI SAM

Duration

Self-Directed

About

The GI SAM: Bleeding and Motility module is comprised of 31 board-style questions highlighting the medical knowledge needed by gastroenterologists for treatment of bleeding as well as common motility therapies. By identifying knowledge gaps and providing resources for self-directed learning, this module will serve as a useful tool in studying for the board exam as well as meeting the needs of a life-long learner.

  • Earn up to 10 AMA PRA Category 1 Credits™ and 10 points towards ABIM Maintenance of Certification (MOC).
  • References for further study.
  • Detailed images to further clarify important points.
  • Can be accessed anytime, anywhere.

Who Should Take this Course

This activity is intended for gastroenterologists, GI fellows, nurse practitioners, physician assistants and other health-care professionals who treat GI disorders.

Takeaways

Upon completing this educational activity, successful learners will be able to:

  • Understand the initial management and outcome data of patient with upper GI bleeding.
  • Understand treatment options for patients with varying severity of peptic ulcer disease.
  • Understand the different methods for correcting coagulopathy in a patient with massive GI bleeding.
  • Select the best test for evaluation and treatment of lower GI bleeding or obscure overt GI bleeding.
  • Review causes of management of bleeding after diagnostic or therapeutic procedures.
  • Recognize chronic constipation and identify best methods for treatment.
  • Understand diagnosis and treatment of chronic diarrhea.
  • Recognize treatment methods for various cases of pseudo-obstruction.

About the Instructors

Series Editor
John F. Kuemmerle, MD, AGAF
Virginia Commonwealth University
Associate Series Editor
Seth R. Sweetser, MD
Mayo Clinic College of Medicine

Authors

Bleeding
Todd H. Baron, Sr., MD
Motility (Upper)
John E. Pandolfino, MD, AGAF
Motility (Lower)
Adil E. Bharucha, MD, MBBS

CME/MOC Information

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Successful completion of this CME activity enables the participant to earn up to 10 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points

MOC/CME expiration date: February 13, 2018

Faculty Relationship and Financial Disclosures

Todd H. Baron, Sr., MD
Disclosed no relevant financial relationships.

Adil E. Bharucha, MD, MBBS
Consulting: Asubio Pharmaceuticals, Ironwood Pharmaceuticals, GICare Pharmaceuticals and Medspira Inc.
Licensed a patent to Medspira Inc.

John F. Kuemmerle, Jr., MD, AGAF
Consulting: UCB, Shire Pharmaceuticals, AbbVie, Procter & Gamble, Elan
Speaking and Teaching: UCB

John E. Pandolfino, MD, AGAF
Consulting: Given
Grant/Research Support: Given
Speaking and Teaching: Given, AstraZeneca Pharmaceuticals

Seth R. Sweetser, MD
Disclosed no relevant financial relationships

More on Continuing Education

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

Jan. 9, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

Nov. 14, 2017

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.